follow us
disclaim warranti liabil
due number sourc inform servic acquisdata pti ltd servic obtain
inher hazard electron distribut may delay omiss inaccuraci inform
servic acquisdata pti ltd affili agent sale repres distributor licensor
warrant accuraci complet current merchant abil fit particular purpos
inform servic avail acquisdata pti ltd servic event acquisdata pti ltd
affili agent sale repres distributor licensor liabl license anyon els loss
injuri caus whole part conting beyond control procur compil interpret edit write
report deliv inform servic acquisdata pti ltd servic event acquisdata
pti ltd affili agent sale repres distributor licensor liabl license anyon els
decis made action taken license relianc upon inform servic consequenti
special similar damag even advis possibl damag license agre liabil
acquisdata pti ltd affili agent sale repres distributor licensor aris kind
legal claim whether contract tort otherwis way connect acquisdata pti ltd servic shall
exceed amount license paid use acquisdata pti ltd servic twelv month immedi
preced event give rise claim
third-quart ep third-quart non- ep
compani narrow full-year revenu rang billion billion includ
minim impact foreign exchang
compani narrow lower full-year ep rang narrow
rais full-year non-gaap ep rang includ approxim
percent neg impact foreign exchang
result studi keytruda combin axitinib first-lin treatment
advanc astat renal cell carcinoma primari endpoint overal surviv progression-fre
compani announc percent increas quarterli dividend cent per outstand share
author addit billion share repurchas includ billion acceler share repurchas
thursday octob edt
kenilworth -- busi -- merck nyse known msd outsid unit state
canada today announc financi result third quarter
built strong momentum quarter believ merck well-posit continu creat
sustain valu sharehold patient said kenneth frazier merck chairman ceo focus
execut drive oper result keytruda make differ cancer patient around world
also continu advanc broad pipelin includ oncolog vaccin hospit specialti well
anim health strong perform highli confid portfolio strategi pipelin
demonstr announc capit return action today
million except ep amount
non-gaap net incom exclud item list
non-gaap ep exclud item list
world-wide sale billion third quarter increas percent compar third
quarter includ percent neg impact foreign exchang sale increas third quarter
partial attribut reduct sale third quarter approxim million due
borrow center diseas control prevent cdc pediatr vaccin stockpil
gardasil human papillomaviru vaccin recombin vaccin prevent certain hpv-relat
cancer diseas driven part temporari product shutdown result cyber-attack
occur june well overal higher demand origin plan addit sale third
quarter unfavor affect approxim million lost revenu certain market relat
cyber-attack
gener accept account principl earn loss per share assum dilut ep
third quarter non-gaap ep third quarter exclud acquisition- divestiture-
relat cost restructur cost charg million relat termin collabor agreement
samsung bioepi co ltd samsung insulin glargin certain item year-to-d result found
attach tabl
merck continu expand oncolog program advanc develop program keytruda
pembrolizumab compani therapi lynparza olaparib parp inhibitor co-develop
co-commerci astrazeneca lenvima lenvatinib mesyl oral avail tyrosin kinas inhibitor
co-develop co-commerci eisai co ltd eisai
merck announc base result trial food drug
administr fda european commiss ec approv keytruda combin
pemetrex platinum chemotherapi first-lin treatment patient metastat nonsquam
non-smal cell lung cancer nsclc egfr genom tumor aberr
merck announc fda grant prioriti review new supplement biolog licens applic
seek approv keytruda monotherapi first-lin treatment local advanc metastat
nonsquam squamou nsclc patient whose tumor express tumor proport score tp
without egfr genom tumor aberr base result pivot phase
trial fda set pdufa date jan
merck announc top-lin result pivot phase trial studi keytruda
combin axitinib first-lin treatment advanc metastat renal cell carcinoma
met primari endpoint overal surviv os progression-fre surviv
demonstr combin made statist signific clinic meaning improv
merck announc interim result pivot phase trial studi keytruda
monotherapi combin chemotherapi first-lin treatment recurr metastat
head neck squamou cell carcinoma met primari endpoint demonstr
monotherapi combin therapi show significantli improv os compar standard care
result present european societi medic oncolog esmo congress
merck announc committe medicin product human use chmp european
medicin agenc ema adopt posit opinion keytruda adjuv therapi treatment
patient melanoma base signific recurrence-fre surviv benefit demonstr
keytruda pivot phase trial
merck announc first present result phase trial evalu
keytruda previously-tr patient high-risk non-muscl invas bladder cancer esmo
congress keytruda demonstr complet respons rate nearli percent
merck astrazeneca announc detail result phase trial test lynparza
mainten treatment patient newly-diagnos advanc brca-mut ovarian cancer
complet partial respons follow first-lin standard platinum-bas chemotherapi result
trial confirm statistically-signific clinically-meaning improv lynparza
compar placebo reduc risk diseas progress death percent month
follow-up median patient treat lynparza reach compar month
patient treat placebo result present esmo congress publish
simultan on-line new england journal medicin
merck eisai announc fda approv lenvima first-lin treatment patient
unresect hepatocellular carcinoma lenvima also approv use china china
nation drug administr europ ec
merck eisai announc fda grant breakthrough therapi design lenvima
combin keytruda potenti treatment patient advanc and/or metastat non-
microsatellit instabl high/profici mismatch repair endometri carcinoma progress
follow least one prior system therapi third breakthrough therapi design
lenvima second breakthrough therapi design lenvima combin keytruda
clinic data merck earli pipelin present esmo congress octob addit data
program present societi immunotherapi cancer meet novemb
esmo merck present number dataset earli pipelin
sting agonist first-in-human data merck phase program studi
monotherapi combin keytruda patient advanc solid tumor
rig-i data merck phase trial studi advanc recurr tumor
cavatak data merck phase trial studi combin
keytruda treatment nsclc bladder cancer
data merck phase trial studi combin keytruda
treatment advanc solid tumor
merck present
data merck phase trial studi monotherapi combin
keytruda treatment advanc solid tumor
tigit data merck phase trial studi monotherapi combin
keytruda treatment patient solid tumor
compani continu advanc vaccin antibiot hiv pipelin
fda approv expand age indic gardasil use women men age
merck announc pivot phase clinic studi evalu compani antibiot zerbaxa
ceftolozan tazobactam investig dose treatment adult patient either
ventil hospital-acquir bacteri pneumonia ventilator-associ bacteri pneumonia met pre-
specifi primari endpoint demonstr non-inferior meropenem activ compar day
all-caus mortal clinic cure rate test-of-cur visit base result merck plan
submit supplement new drug applic fda ema seek regulatori approv zerbaxa
potenti new indic
merck announc fda approv two new medicin indic treatment
infect adult patient prior antiretrovir treatment experi delstrigo once-daili fixed-
dose combin tablet doravirin mg lamivudin mg tenofovir disoproxil fumar
tdf mg pifeltro doravirin mg new non-nucleosid revers transcriptas inhibitor
administ combin antiretrovir medicin chmp ema adopt
posit opinion recommend grant market author delstrigo pifeltro
treatment adult infect without past present evid resist non-nucleosid
revers transcriptas class lamivudin tenofovir
follow tabl reflect sale compani top pharmaceut product well sale anim health
million
m-m-r ii varivax
third-quart pharmaceut sale increas percent billion includ percent neg impact
foreign exchang addit factor mention summari increas primarili
driven growth oncolog hospit acut care partial off-set lower sale virolog on-going
impact loss market exclus sever product
growth oncolog driven signific increas sale keytruda reflect compani continu
launch new indic global strong momentum treatment patient nsclc
keytruda approv first-lin set addit oncolog sale reflect allianc
revenu million relat lynparza million relat lenvima repres merck share profit
product sale net cost sale commerci cost
growth hospit acut care reflect strong demand unit state bridion sugammadex inject
mg/ml medicin revers neuromuscular blockad induc rocuronium bromid vecuronium
bromid adult undergo surgeri strong global demand noxafil posaconazol medicin
prevent invas fungal infect
vaccin perform reflect higher sale gardasil papillomaviru quadrival type
vaccin recombin gardasil vaccin prevent certain cancer diseas caus
hpv unit state attribut cdc stockpil borrow third quarter describ
previous growth intern market primarili due higher sale europ on-going commerci
launch china vaccin perform neg affect signific decreas sale zostavax
zoster vaccin live vaccin prevent herp zoster primarili due approv competitor
product receiv preferenti recommend advisori committe immun practic
octob compani anticip futur sale zostavax continu unfavor affect
pharmaceut sale growth quarter partial off-set lower sale virolog larg reflect
signific declin zepati elbasvir grazoprevir medicin treatment chronic hepat viru
genotyp infect due increas competit declin patient volum compani expect
continu
pharmaceut sale growth quarter also partial off-set on-going impact loss market
exclus zetia ezetimib vytorin ezetimibe/simvastatin medicin lower cholesterol
biosimilar competit remicad infliximab treatment inflammatori diseas compani market
territori europ
anim sale total billion third quarter increas percent compar third
quarter includ percent neg impact foreign exchang growth primarili driven higher
sale companion anim product predominantli bravecto fluralan line product kill flea
tick dog cat week growth also driven higher sale livestock product includ
rumin poultri product
anim segment profit million third quarter increas percent compar
million third quarter
third-quart expens ep relat inform
tabl present select expens inform
million
acquisition-
materi product
market administr
research develop
materi product
market administr
research develop
gaap expens ep relat inform
gross margin percent third quarter compar percent third quarter
decreas gross margin third quarter primarili driven charg relat
termin collabor agreement samsung decreas partial off-set favor effect
foreign exchang well cost record third quarter relat cyber-attack addit
lower net impact acquisition- divestiture-rel cost restructur cost reduc gross margin
percentag point third quarter compar percentag point third quarter
also partial off-set margin declin
market administr expens billion third quarter declin percent compar
third quarter reflect lower direct sell promot cost well favor effect
foreign exchang larg off-set higher administr cost
research develop expens billion third quarter compar billion
third quarter declin primarili reflect billion charg record third quarter
relat format collabor astrazeneca lower in-process research develop ipr
impair charg partial off-set increas clinic develop spend particular oncolog higher
licens cost invest discoveri earli drug develop
gaap ep third quarter compar third quarter
non-gaap expens ep relat inform
non-gaap gross margin percent third quarter compar percent third
quarter increas predominantli due favor effect foreign exchang well cost
record third quarter relat cyber-attack
non-gaap market administr expens billion third quarter compar
third quarter reflect lower direct sell promot cost well favor effect foreign
exchang off-set higher administr cost
non-gaap expens billion third quarter increas percent compar
third quarter increas primarili reflect higher clinic develop spend particular oncolog
higher licens cost invest discoveri earli drug develop
non-gaap ep third quarter compar third quarter
reconcili non- net incom ep provid tabl follow
million except ep amount
non-gaap ep exclud item list
non-gaap net incom exclud item list
decreas increas net incom due exclud item
acquisition- divestiture-rel
charg relat termin collabor agreement samsung
charg relat format collabor astrazeneca
net decreas increas incom tax
decreas increas net incom
merck narrow full-year revenu rang billion billion includ minim
impact foreign exchang current exchang rate
merck narrow lower full-year ep rang chang
gaap ep rang reflect inclus charg relat termin collabor agreement
samsung merck narrow rais full-year non-gaap ep rang
includ approxim percent neg impact foreign exchang current exchang rate non-
rang exclud acquisition- divestiture-rel cost cost relat restructur program charg
relat format eisai collabor viralyt acquisit charg relat termin
collabor agreement samsung certain item
follow tabl summar compani financi guidanc
higher low- mid-singl
billion
billion
lower low- mid-singl
compani non-gaap adjust revenu
ep guidanc assum share count assum dilut approxim billion share
reconcili anticip ep non- ep item exclud non- ep
provid tabl
million except ep amount
non-gaap ep exclud item list
acquisition- divestiture-rel
charg relat format collabor eisai
charg relat termin collabor agreement samsung
charg viralyt acquisit
net decreas increas incom tax
decreas increas net incom
expect full-year effect tax rate percent percent reflect unfavor impact
approxim percentag point item
merck board director approv percent increas compani quarterli dividend rais
per share per share compani outstand common stock payment made jan
sharehold record close busi dec board also author addit
billion treasuri stock purchas time limit complet compani enter billion
acceler share repurchas program expand author
addit compani also plan invest approxim billion new capit project
billion prior billion commit announc februari
acquisdata proud host leagu estim want opportun win free
subscript join acquisdata media telecommun leagu
today merck global health care leader work help world well merck known msd outsid
unit state canada prescript medicin vaccin biolog therapi anim health
product merck work custom oper countri deliv innov health solut
merck also demonstr commit increas access health care far-reach polici program
partnership
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
aenova group one world lead compani pharmaceut healthcar industri europ
aenova one lead contract manufactur rang servic cover entir valu chain
develop manufactur common dosag form solid semi-solid liquid product group
medicin dietari supplement group oper site nine european countri asia usa
twelv site headquart locat germani aenova employe
 braun one world lead healthcar supplier braun four divis orient product
servic toward differ medic field hospit surgeri privat practic medic care doctor offic
bayer innov compani histori core compet field health care
agricultur develop new molecul use innov product solut improv health
human anim plant bayer research develop activ base profound understand
biochem process live organ
boehring ingelheim group one world lead pharmaceut compani headquart
ingelheim germani boehring ingelheim oper global affili employe
focu family-own compani found research develop manufactur market
new medic high therapeut valu human veterinari medicin
umbrella tecdax-list compani carl zeiss meditec ag one world lead
medic technolog compani medic technolog activ zeiss bundl carl zeiss ag hold
interest carl zeiss meditec ag jena germani parent compani carl zeiss meditec
group compris addit subsidiari carl zeiss meditec inc carl zeiss meditec iberia
desitin arzneimittel gmbh activ intern germani switzerland scandinavia eastern europ level
hamburg plant produc sophist product treatment neurolog psychiatr ill
offer larg number establish innov product especi core indic epilepsi
parkinson syndrom optim pharmacotherapi continu develop cooper
future-ori compani treat diseas central nervou system one desitin main area
activ invest
freseniu global healthcar group offer high-qual product servic dialysi hospit
outpati treatment employe countri around globe annual sale
exceed billion freseniu one world lead healthcar compani freseniu group includ
four independ oper busi segment one activ major growth area healthcar freseniu
medic world leader treat peopl chronic kidney failur freseniu helio germani largest
hospit oper freseniu kabi suppli essenti drug clinic nutrit product medic devic servic
help critic chronic ill patient freseniu vame plan develop manag healthcar facil
freseniu medic world largest integr provid product servic individu undergo
dialysi chronic kidney failur condit affect around million individu world-wide
network dialysi clinic north america europ latin america asia-pacif africa freseniu
medic provid dialysi treatment patient around globe freseniu medic also
world lead provid dialysi product hemodialysi machin dialyz relat dispos
grnenthal group independ family-own intern research-bas pharmaceut compani
headquart aachen germani grnenthal one five remain research-ori pharmaceut
compani headquart germani sustain invest research develop research
develop cost amount percent revenu grnenthal research develop
strategi concentr select field therapi state-of-the-art technolog compani focus
discov new way treat pain better effect fewer side-effect current therapi
human healthcar togeth
merz pharma independ intern aesthet neurotoxin compani research
develop capabl continu growth market leadership aesthet neurotoxin result
drive innov along focus strateg acquisit continu expand across area
busi due focus purpos approach includ organ inorgan growth privately-
held family-own compani histori believ take long-term view
morphosi develop hucal success antibodi librari technolog pharmaceut industri
success appli patent technolog morphosi becom leader field
therapeut antibodi one
pharmaceut partner morphosi built therapeut pipelin human antibodi drug
candid treatment cancer rheumatoid arthriti alzheim diseas name
on-going commit new antibodi technolog drug develop morphosi focus make
healthcar product tomorrow morphosi list frankfurt stock exchang symbol mor
hartmann group one lead european provid medic hygien product core
compet wound treatment wound dress negative-pressur wound therapi conform bandag
plaster incontin care dispos incontin brief pad well product skin care case
incontin infect protect surgic drape oper theatr cloth dispos surgic
instrument disinfect portfolio supplement product compress therapi first aid
compani headquart heidenheim germani whose prioriti market europ oper around
world employe hartmann group gener sale eur million
engin innov employ peopl compani provid healthcar germani
harmon qualiti medic care sound busi model good busi judgment
tada publicli trade intern compani focu healthcar market
perfect combin tradit innov attract cost
germani best intern locat research product distribut pharmaceut
except high level direct access intern renown scientist outstand research unit major
pharmaceut market make germani uniqu busi locat develop world popul
structur creat new challeng lead increas demand pharmaceut togeth
signific advanc medic biotechnolog research give pharmaceut industri new impetu
addit central locat heart europ germani offer excel well-develop nationwid
infrastructur modern transport network work coordin high-qual commun
energi infrastructur hundr thousand highli qualifi worker area medic technolog
pharmaceut technolog mechan engin enabl compani implement effici complex
product process pharmaceut compani germani also benefit close proxim lead
machin plant manufactur ensur continu product process reduc downtim germani
account approxim total product machineri plant europ
research develop
germani becom one world import countri clinic studi germani leader
industry-initi clinic studi europ second world-wide dens network univers faculti
well varieti research institut affili univers speak favor germani busi locat
benefit assess review negoti problem conflict
legislatur creat act restructur pharmaceut market amnog includ difficult
compon term mandatori discount price moratorium earli benefit assess directli
massiv impact exist busi model especi procedur earli benefit assess
establish process complex complic place question
facilit easier categor individu aspect procedur develop interact
inform graphic cooper rztezeitung illustr process earli benefit assess
includ parti involv result problem conflict
associ research-bas pharmaceut compani vfa
earli german associ research-bas pharmaceut compani vfa
vfa repres interest global leader research-bas pharmaceut compani
subsidiari affili compani healthcar research econom polici
german associ pharmaceut industri bpi
servic provid compani field biotechnolog herbal medicin homeopathy/anthroposophi
german associ produc
member member among pharmaceut industri associ
germani member primarili pharmaceut produc also pharmacist lawyer publish agenc
well market opinion research institut healthcar field
generika associ compani manufactur gener biosimilar product germani
generika member compani germani compani manufactur gener biosimilar product
togeth cover percent medicin drug requir statutori health insur fund
bundesverband der arzneimittel-herstel german medicin manufactur associ
repres interest pharmaceut industri germani compris intern compani well
local small medium enterpris sme compani membership lead trade organ
pharmaceut industri germani
cover entir rang industri landscap self-med medicin over-the-counter prescript
drug rx medic devic
advoc secur respons self-med profession medic pharmaceut advic
therefor strongli support statutori protect owner-oper pharmaci primari institut
addit commit free fair clean advertis promot principl regist
activ take part public health polici discuss compet refer public author
policymak institut german healthcar sector
member inform relev regulatori legisl procedur nation european level
offer scientif hands-on advic scientif servic organ widi
repres member european level brussels-bas aesgp associ european
self-med industri furthermor associ wsmi world self-med industri feder
member associ contin
work pharmaceut compani germani greatli hamper recent year due legisl
measur sever step tighten discount regul caus legal mandat manufactur discount
tripl sinc addit discount increas substanti recent year base individu agreement
overal manufactur receiv half sell price drug sector statutori
health insur report increas spend last year expenditur pharmaceut actual decreas
main driver behind spend pharmaceut price actual decreas year
increas consumpt result age societi avail new improv pharmaceut
treatment sever life-threaten diseas
third shi expenditur eur billion total eur billion spent hospit treatment togeth
expenditur care doctor eur billion percent pharmaceut eur billion percent
make anoth third eur billion spent administr cost increas mandatori manufactur
discount result percent decreas expenditur pharmaceut compar
associ research-bas pharmaceut compani vfa
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
